2020 North American Menopause Society (NAMS) Virtual Annual Meeting

Novel non-hormonal therapy may reduce hot flashes, improve QoL in postmenopausal women

Roshini Claire Anthony, 20201021180001

NT-814, an oral, non-hormonal dual neurokinin 1,3 receptor antagonist may reduce the frequency of hot flashes, while improving quality of life (QoL) and sleep in postmenopausal women, according to results of the phase IIb SWITCH-1 trial presented at NAMS 2020.

Number, severity of menopausal symptoms may up CV risk

Roshini Claire Anthony, 20201019180001

Women who experience two or more moderate or severe menopausal symptoms may have an elevated risk of cardiovascular disease (CVD) or strokes, according to a study presented at NAMS 2020.

Midlife women still desire a home run

Audrey Abella, 20201013140000

Contrary to the common belief that women’s interest in sex fades as they age, a study presented at NAMS 2020 revealed that about 25 percent of women in their midlife continue to rate sex as important.

Suvorexant beneficial for VMS-associated insomnia in midlife women

Audrey Abella, 20201013100000

The dual orexin receptor antagonist suvorexant was effective in managing VMS*-associated insomnia among women in midlife, with further benefits for self-reported night-time, but not daytime, VMS, according to data presented at NAMS 2020.

Vaginal softgel benefits older women with vulvovaginal atrophy

Audrey Abella, 20201012105230

Use of the self-administered TX-004HR – an applicator-free, ultra-low-dose, 17β-oestradiol softgel vaginal insert – led to significant improvements in the symptoms of vulvovaginal atrophy (VVA) such as moderate-to-severe dyspareunia and vaginal dryness in postmenopausal women aged >60 years, according to updated results from the phase III REJOICE trial presented at NAMS 2020.

Hormone therapy protects the heart by lowering inflammation

Pearl Toh, 20201010141000

One way how hormone therapy with oestradiol may slow the progression of atherosclerotic cardiovascular disease (CVD) in postmenopausal women is through the reduction of inflammatory biomarkers, according to the ELITE* study presented at the NAMS 2020 Annual Meeting.